Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kwality PharmaceuticalsNSE:KPL +5.15%60 3-Year EBITDA Growth Rate is 37.20% as of Jun. 2026, which is 1% below its 10-year median of 37.40. GuruFocus rates NSE:KPL with a GF Score™ of 60/100 and a GF Value™ of ₹1,332.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, Kwality Pharmaceuticals ranks better than 84.18% on this metric.
During the past 12 months, Kwality Pharmaceuticals's average EBITDA Per Share Growth Rate was 54.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 37.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 14.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 31.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kwality Pharmaceuticals was 120.60% per year. The lowest was -22.30% per year. And the median was 37.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Kwality Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
NSE:KPL vs : 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kwality Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kwality Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kwality Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Kwality Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 37.20% mean?
Kwality Pharmaceuticals (NSE:KPL) has a 3-Year EBITDA Growth Rate of 37.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kwality Pharmaceuticals and its competitors. This is near median its historical median of 37.40. According to the industry distribution chart, Kwality Pharmaceuticals ranks #128 out of 809 companies in the Drug Manufacturers industry, placing it in the top 15.8%.
Is Kwality Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Kwality Pharmaceuticals' current 3-Year EBITDA Growth Rate of 37.20% is near median its 10-year median of 37.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Kwality Pharmaceuticals' value of 37.20% is 318% above this industry median. Based on the distribution chart, Kwality Pharmaceuticals ranks #128 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kwality Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kwality Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ?
According to the Drug Manufacturers industry distribution chart, Kwality Pharmaceuticals ranks #128 out of 809 companies for 3-Year EBITDA Growth Rate. This places Kwality Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Kwality Pharmaceuticals' value of 37.20% is 318% above this benchmark. While the company's 10-year median is 37.40 vs. the industry median of 8.90, Kwality Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kwality Pharmaceuticals's current 3-Year EBITDA Growth Rate of 37.20% is 318% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kwality Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kwality Pharmaceuticals's current 3-Year EBITDA Growth Rate is 37.20%, which is near median its own 10-year median of 37.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kwality Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Kwality Pharmaceuticals (NSE:KPL) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,332.01, compared to a current price of ₹3,630.30 — trading 172.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 37.20%, which is near median its 10-year median of 37.40 and 318% above the Drug Manufacturers industry median of 8.90. Kwality Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kwality Pharmaceuticals (NSE:KPL), the current 3-Year EBITDA Growth Rate is 37.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kwality Pharmaceuticals (NSE:KPL) Overvalued in 2026?
Based on GuruFocus' analysis, Kwality Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹3,630.30 is trading 172.5% above its estimated GF Value™ of ₹1,332.01.
GuruFocus considers Kwality Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:KPL:
3-Year EBITDA Growth Rate: 37.20% (near median its 10-year median of 37.40)
GF Value™: ₹1,332.01 vs. price of ₹3,630.30 (172.5% above fair value)
Industry Position: 318% above the Drug Manufacturers median (#128 of 809)
No single metric tells the full story. See the NSE:KPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kwality Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables.
60GF Score
Get the complete analysis for NSE:KPL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KPL has been successfully added to your 
